Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: kraig peterson who wrote (91)	10/1/2000 5:25:30 PM
From: scott_jiminez	Respond to of 278

Thanks for the input Kraig. I've no comment on MitoKor since I'm unfamiliar with 'mitochondrial applications into therapeutic research'. I believe I heard about Medinox at some point in the past; I've stated earlier my opinions about the complexity of nitric oxide/superoxide etc. oxygen-radical related biochemistry and the difficulty in harnessing this for effective therapies. I have direct experience in quite confusing data when iNOS (the anabolic enzyme for NO synthesis) is blocked or eliminated (the iNOS knockout mouse) in a mouse model for multiple sclerosis. Medinox claims to have compounds which modulate NO levels...as opposed to completely inhibiting the enzyme. Worth a glance. I've also stated publicly that 'Neuroinvestment' provides a valuable service for some, although not all, investors interested in neuro-related companies. My statement earlier this year regarding Cephalon's Provagil and ADHD (http://www.siliconinvestor.com/readmsg.aspx?msgid=13756232) and the negative results reported soon thereafter (http://biz.yahoo.com/prnews/000731/pa_cephalo.html) is a case study where knowing the science, rather than the state of the clinical trials (and the PR noise from the company), is a much more OBJECTIVE approach to analyzing a drug candidate's prospects for lucrative indications. Scott